Pyrazolopyrimidine mGlu5 Antagonists Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mGlu5 receptor antagonists have limitations in effectively targeting metabotropic glutamate 5 receptors, particularly in states of glutamatergic hyperactivity, and existing pyrazolopyrimidines either show activity on unrelated targets like 11β-hydroxysteroid dehydrogenase type 1 or lack specificity as mGlu5 receptor antagonists.
Innovation Solution
Development of novel pyrazolopyrimidines that specifically act as antagonists of the metabotropic glutamate 5 receptor, demonstrating minimal activity on 11β-hydroxysteroid dehydrogenase type 1, thereby providing therapeutic potential for glutamatergic hyperactivity-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pyrazolopyrimidines are used as mGlu5 receptor antagonists, then some level of receptor inhibition is achieved, but they either show activity on unrelated targets like 11β-hydroxysteroid dehydrogenase type 1 or lack specificity as mGlu5 receptor antagonists
Solution Approach 1:
The patent applies local quality by making specific modifications to particular positions on the pyrazolopyrimidine core structure. Different substituents are introduced at specific locations (R1, R2, R3, R4, R5, R6 positions) to optimize mGlu5 receptor binding while minimizing off-target effects. This localized structural tailoring allows differentiation between compounds that bind to mGlu5 versus those that bind to 11β-HSD1.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (halogens, alkyl groups, aryl groups), substituent positions, and molecular weight ranges to achieve selective mGlu5 antagonism. By changing these chemical parameters and evaluating their impact on both mGlu5 activity and 11β-HSD1 activity, the invention identifies optimal parameter combinations that provide desired specificity.
2Reliability
If current mGlu5 receptor antagonists are used, then some therapeutic effect is achieved, but they are not effective enough in states of glutamatergic hyperactivity
Solution Approach 1:
The patent develops a series of compounds with varying degrees of potency and selectivity to match different physiological states. The dynamic range of activity is optimized so that compounds can effectively inhibit mGlu5 receptors during glutamatergichyperactivity while maintaining appropriate activity levels under basal conditions. This allows the medication to adapt its effectiveness to the patient's current physiological state.
Solution Approach 2:
The invention optimizes key pharmacological parameters including binding affinity (IC50 values), selectivity ratios (mGlu5 versus 11β-HSD1), and functional potency to enhance therapeutic effectiveness. By systematically varying these parameters across the compound series, the patent identifies optimal values that maximize efficacy in glutamatergichyperactivity states while minimizing side effects.
Data Source
AI summary
This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.